Stites v. Eli Lilly and Company | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Stites v. Eli Lilly and Company

Sort by

Viewing results 1‒25 of 1010

Drugs research
Novo Nordisk and Eli Lilly set to face new challenger in weight-loss race
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
January 23, 2024
Biotech
Drugmakers race to find alternative suppliers as US cracks down on Chinese biotech
...Eli Lilly and Vertex declined to comment on the talks....
April 11, 2024
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Novo Nordisk AS
Novo Nordisk chief seeks more deals to cement weight-loss lead amid ‘hype’
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
March 8, 2024
Novo Nordisk AS
Novo to use Ozempic and Wegovy windfall to invest $7bn a year by 2030
...Eli Lilly chief executive David Ricks described the acquisition as “unusual” on Tuesday and called for competition authorities to look into the deal....
February 12, 2024
Eli Lilly & Co
Eli Lilly weight-loss drug found to address sleep apnoea in trial
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
April 17, 2024
News updates from March 12: US House votes through bill to ban TikTok; Geert Wilders announces he will not be Netherlands PM
Eli Lilly teams with Amazon to dispense Zepbound and other medication
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
March 13, 2024
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Eli Lilly & Co
Eli Lilly strikes drug dispensing deal with Amazon
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
March 13, 2024
Eli Lilly & Co
US regulator delays decision on Eli Lilly’s Alzheimer’s drug donanemab
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
March 8, 2024
LexHelen Thomas
The Lex Newsletter: Living in an Ozempic world Premium content
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
March 15, 2024
News in-depthEli Lilly & Co
Eli Lilly races to boost capacity as it rolls out rival to Novo Nordisk weight-loss drug
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
March 5, 2024
News updates from February 6: US court denies Trump presidential immunity, Boeing jet in Alaska Airlines blowout was missing bolts
Eli Lilly says diabetes and obesity drugs will boost sales by 20% this year
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
February 6, 2024
LexEli Lilly & Co
Eli Lilly’s heavyweight status looks set to last Premium content
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
January 16, 2024
Amazon.com
Amazon hopes anti-obesity drug demand will boost pharmacy business
...Amazon Pharmacy stands to generate “a lot of revenue” from drugs such as Eli Lilly’s Zepbound injection and Novo Nordisk’s Wegovy, which are both available to patients directly through the Amazon website...
March 26, 2024
Drugs research
Eli Lilly’s weight-loss drug set for UK launch ‘within weeks’
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
January 25, 2024
Eli Lilly & Co
Eli Lilly calls for scrutiny of rival Novo Nordisk’s deal to expand production of weight-loss drug
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
February 6, 2024
FT Live
Infrastructure Investment in Latin America and the Caribbean
Identifying opportunities for investors and asset managers
Wednesday, 12 June237 Park Avenue, New York, NY, USA
News in-depthDrugs research
The race to develop the next generation of weight-loss drugs
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
April 1, 2024
News in-depthDementia
Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
April 22, 2024
Drugs research
Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results
...US biotech Viking Therapeutics’ shares more than doubled after trial data for the company’s weight-loss drug outperformed existing treatments from drugmakers Novo Nordisk and Eli Lilly....
February 27, 2024
News updates from November 8: Iger pledges another $2bn in Disney cost cuts, Draghi delivers downbeat EU forecast
US approves Eli Lilly’s injectable weight loss drug
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
November 8, 2023
News updates from November 2: Sam Bankman-Fried convicted, BoE leaves rates unchanged
Eli Lilly lowers earnings forecast due to acquisition-related costs
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
November 2, 2023
Pharmaceuticals sector
Approval for Eli Lilly obesity drug sets up rival to Wegovy
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
November 9, 2023
Pharmaceuticals sector
Novo Nordisk and Eli Lilly hoover up smaller obesity drug groups
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
October 24, 2023
Drugs research
Diabetes drug offers hope to Parkinson’s sufferers
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
April 3, 2024
LexMergers & Acquisitions
Eli Lilly: Point acquisition gives battered biotech sector a boost Premium content
...In addition, Point held about $434.8mn in cash, cash equivalents and investments at the end of June. This is a very small deal for a company as big as Eli Lilly....
October 3, 2023
Eli Lilly & Co
Eli Lilly to buy cancer specialist Point for $1.4bn
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
October 3, 2023

Previous pagePage 1 of 41Next page